Betsy Q. Cliff, Michael Rozier, et al.
May 22, 2017
Over the next ten years, President Trump’s FY 2018 budget proposal would cut Obamacare by $1.25 trillion, reducing the deficit by $250 billion, through the AHCA. Beyond that, Trump’s budget would cut Medicaid spending by $610 billion and cut CHIP by $5.8 billion (while extending it through 2019).
Despite the drive toward value-based health care reimbursement and patients’ ever increasing financial stake in their own health care treatment, many traditional value assessment tools fail to consider value from the patient’s perspective.
On May 22, 2017, the House of Representatives and the Department of Justice jointly asked the District of Columbia Court of Appeals to continue to hold House v. Price in abeyance. This would mean continued uncertainty for insurers and the marketplaces.
Coverage arrangements in most insurance plans are designed under principles of equality rather than equity. To fully realize the benefits of medical advances, ensure access for those who could benefit most, and enhance the efficiency of our health care expenditures, we need to change this paradigm.
Palliative care has been increasing in prevalence, in part due to new value-based care incentives. However, there is a significant misunderstanding about what defines effective palliative care among patients and providers.
California, New York Lead Group Of States Seeking To Intervene In Litigation Over Cost-Sharing Reduction Payments
On May 18, 2017, attorneys general from fourteen states and the District of Columbia, led by California and New York, filed a motion to intervene in House v. Price, the House’s challenge to reimbursement of insurers for cost-sharing reduction payments required under the Affordable Care Act.
Improving and reforming our health care delivery system is not a partisan issue. It is important for Congress, the Trump administration, and the health care industry to continue bipartisan efforts to shift our health care delivery system and provider payment models toward value-based care.
When it comes to health care, consumers aren’t able to easily obtain measures that could help them understand their quality of care. This isn’t because we don’t have quality measures, rather what we have are numerous “production” measures, but very few “consumer” measures.
While the development of new antimicrobials to combat antimicrobial resistance would seem to offer high value, our current system offers insufficient incentives to invest in them. Policy interventions that dampen the tie between manufacturer profits and the volume of antimicrobial use are needed.
On May 17, CMS released a guidance outlining a new “proxy direct enrollment pathway” that will be available for the 2018 individual market open enrollment period. The process is designed to reduce regulatory burden and provide more choices for consumers, but it also carries risks for consumers.